OncoNano Medicine Revenue and Competitors
Estimated Revenue & Valuation
- OncoNano Medicine's estimated annual revenue is currently $2.6M per year.
- OncoNano Medicine's estimated revenue per employee is $77,500
- OncoNano Medicine's total funding is $119.7M.
Employee Data
- OncoNano Medicine has 33 Employees.
- OncoNano Medicine grew their employee count by -23% last year.
OncoNano Medicine Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 200% | N/A | N/A |
#2 | $15.8M | 102 | 34% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $2.8M | 18 | -25% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.6M | 15 | 50% | N/A | N/A |
#7 | $7.6M | 49 | 23% | N/A | N/A |
#8 | $0.9M | 6 | -33% | N/A | N/A |
#9 | $1.6M | 10 | -9% | N/A | N/A |
#10 | N/A | 86 | 62% | N/A | N/A |
What Is OncoNano Medicine?
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple and effective identifier of diseased tissue providing a foundation for the development of a broad range of highly targeted therapeutics and imaging agents. Our lead program, ONM-100, targets tumor acidosis to accurately differentiate cancer from healthy tissue for use in surgery.
keywords:N/A
$119.7M
Total Funding
33
Number of Employees
$2.6M
Revenue (est)
-23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
OncoNano Medicine's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Senior Director - Financial Planning & Analysis | |
2 | Clinical Scientist | |
3 | Sr. Director Finance | |
4 | VP Technical Operations | |
5 | CFO | |
6 | Professor | |
7 | Associate Director | |
8 | VP Nonclinical and Translational Medicine | |
9 | VP, Head Clinical Operations | |
10 | VP Operations |
OncoNano Medicine News
OncoNano Medicine Announces Positive Preclinical Data for Tumor Specific Delivery with the ON-BOARD Platform at AACR 2022 Annual Meeting. April...
OncoNano Medicine, Inc., a Southlake, Texas-based completed a $23.7m in a second tranche of Series A financing, bringing the total Series A round to $35.4m. The round was arranged by Salem Partners, who also participated as a principal investor. Proceeds of the financing will accelerate the co ...
OncoNano Medicine, Inc., a Southlake, Texas-based company that provides a pH-activated compound platform for disease detection and treatment, closed a $11.7m Series A financing. The transaction was arranged by Salem Partners, who also participated as a principal investor. The Series A funding s ...
Other Companies in Southlake
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.2M | 35 | 9% | N/A |
#2 | $6.8M | 35 | -3% | N/A |
#3 | $7.6M | 35 | -5% | N/A |
#4 | $7.1M | 35 | 9% | N/A |
#5 | $6.2M | 35 | 0% | N/A |
OncoNano Medicine Executives
| Name | Title |
|---|---|
| Matthew Head | CFO |
| Kartik Krishnan | Chief Medical Officer |
| Marty Driscoll | Chief Executive Officer |
| Don Kruppa | VP Operations |
| Kathy Rath | VP Regulatory Affairs |
| Ruolan Han | VP of Nonclinical and Translational Medicine |
| Brian Ostrander | Vice President, Head of Clinical Operations |